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This study was aimed to investigate the crosstalk between protein kinase C z (PKCz) and signal trans-
ducer and activator of transcription 3 (STAT3) in cardiomyocyte hypertrophy. In neonatal rat car-
diomyocyte hypertrophic model induced by phenylephrine (PE), the levels of phosphorylated PKCz and
phosphorylated STAT3 were signiﬁcantly increased, suggesting the activation of both PKCz and STAT3 in
cardiomyocyte hypertrophy. Overexpression of PKCz by adenovirus infection elevated the expressions of
hypertrophic markers atrial natriuretic factor (ANF) and brains natriuretic polypeptide (BNP), as well as
the cell surface area; while genetic silencing of PKCz inhibited PE-induced cardiomyocyte hypertrophy.
An interaction between PKCz and STAT3 in cardiomyocytes was shown by co-immunoprecipitation ex-
periments. Overexpression of PKCz increased the phosphorylated level of STAT3 at both Ser727 and
Tyr705, promoted the nuclear translocation of STAT3, and enhanced the expression of STAT3 down-
stream target genes c-fos and angiotensinogen (aGT); whereas PKCz knockdown prevented PE-induced
STAT3 activation, nuclear shuttling and transcriptional activation. In conclusion, PKCz interacts with
STAT3 and promotes its activation in cardiomyocyte hypertrophy. Strategies targeting inhibition of PKCz-
STAT3 signaling pathway suggest a therapeutic potential for cardiac hypertrophy.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Cardiac hypertrophy is a common response of the car-
diomyocytes to a variety of physiological and pathological
stimuli. However, prolonged hypertrophy deteriorates the car-
diac function and eventually leads to heart failure. Therefore, it isnal transducer and activator
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d/4.0/).of great importance to inhibit cardiac hypertrophy as a thera-
peutic strategy against heart failure. Cardiac hypertrophy is
commonly associated with upregulation of fetal genes, such as
atrial natriuretic factor (ANF), brain natriuretic polypeptide
(BNP), and genes for fetal isoforms of contractile proteins like b-
myosin heavy chain (b-MHC). However, signaling mechanisms
responsible for the regulation of fetal gene program remain to be
elucidated.
Recent studies suggest that activation of protein kinase C z
(PKCz), a member of the atypical PKC isozymes, is closely related to
the pathogenesis of cardiac hypertrophy. A signiﬁcant upregulation
of PKCz has been observed in the left ventricles of cardiac hyper-
trophy animal model induced by volume overload or by pressure
overload (1e3). Sustained activation of PKCz promotes the
expression of ANF in rat cardiomyocytes (4). Knockout of PKCz
prevents angiotensin II-induced cardiac hypertrophy in vivo (5).
These observations show that PKCz plays an important role in
cardiac hypertrophy.nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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highlighted as a regulator of a wide variety of biological processes,
such as cell survival and apoptosis, inﬂammation and angiogenesis
(6). STAT3 has been found to be important for transducing hyper-
trophic signals in cardiomyocyte hypertrophy (7, 8). Activation of
STAT3 has been observed in cardiac hypertrophy induced by a va-
riety of stress conditions, such as pressure overload (9), acute
myocardial infarction (10), and exposure to angiotensin II (11) or
isoproterenol (12). Transgenic mice with cardiomyocyte-speciﬁc
overexpression of STAT3 develop cardiac hypertrophy with
increased expressions of the hypertrophic markers ANF and b-MHC
(7). Moreover, genes involved in cardiomyocyte hypertrophy, such
as c-fos, ANF and angiotensinogen (aGT), can be regulated by STAT3
(8, 13, 14).
The interactions between PKCz and STAT3 have been proposed
by several studies. As a serine/threonine kinase (2), PKCz regulates
the Janus kinase (JAK)/STAT pathway in inﬂammation (15). Addi-
tionally, PKCz regulates STAT3 activation in pancreatic cancer cells
both in vitro and in vivo (16, 17). However, it is still unknown
whether PKCz regulates STAT3 activation in cardiac hypertrophy.
In this study, we assess the role of PKCz in cardiomyocyte hy-
pertrophy stimulated by phenylephrine (PE), and investigate the
interactions between PKCz and STAT3 in neonatal rat car-
diomyocytes (NRCMs).2. Materials and methods
2.1. Cell culture
Primary culture of NRCMs were isolated from the hearts of 1 to
3-day-old SpragueeDawley (SD) rats using a protocol previously
described (18). The cardiomyocytes were puriﬁed and seeded at a
density of 1  106 cells/well onto 6-well plates, then cultured in
Dulbecco's modiﬁed Eagle's medium supplemented with 10% fetal
bovine serum (FBS) and 5-bromodeoxyuridine (0.1 mM) at 37 C.
After 48 h, the culture medium was replaced by DMEM containing
0.1% FBS, and the cells were further incubated for 16e18 h. Sub-
sequently, the cardiomyocytes were treated with PE for indicated
time.2.2. Plasmid transfection and adenovirus infection
STAT3 plasmid was constructed with pEGFP-N3, and conﬁrmed
by DNA sequencing in Sangon Biotech Co Ltd (Shanghai, China).
Cardiomyocytes were transiently transfected with the plasmid us-
ing Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer's instructions.
Adenovirus expressing PKCz (Ad-PKCz) and GFP vector (Ad-GFP)
were purchased from Vigene Biosciences (China). Cells were
infected to Ad-PKCz or Ad-GFP at the multiplicity of infection (MOI)
of 60 for 48 h before they were harvested for RNA or protein
extraction.2.3. RNA interference
Three different siRNAs for PKCz (S1, S2, and S3) and negative
control siRNA were obtained from Genema (China). The sequences
of siRNAs were shown in Supplemental Material Table S1. NRCMs
were transfected with either PKCz siRNAs or negative control siRNA
using Lipofectamine 2000 according to the manufacturer's in-
structions. At 48 h after the transfection, cells were harvested for
RNA or protein extraction to compare the silencing efﬁcacy of
different duplex siRNAs.2.4. Western blotting and co-immunoprecipitation (co-IP)
Rabbit anti-phospho-PKCz polyclonal antibody (diluted 1:500
for WB, Cell Signaling Technology, USA), rabbit anti-PKCz (C-20)
polyclonal antibody (WB: diluted 1:500, IP: diluted 1:10, Santa
Cruz, CA, USA), rabbit anti-phospho-STAT3 (Ser727) polyclonal
antibody (diluted 1:1000, Cell Signaling Technology), rabbit anti-
phospho-STAT3 (Tyr705) polyclonal antibody (diluted 1:1000,
Cell Signaling Technology), and mouse anti-STAT3 polyclonal
antibody (diluted 1:1000, Cell Signaling Technology) were used in
the experiments. Mouse anti-a-tubulin monoclonal antibody
(diluted 1:10,000, SigmaeAldrich, MO, USA) was served as a
loading control.
30 mg protein extracts was separated by electrophoresis in
SDSePAGE gel, transferred to PVDF membranes (Millipore, USA),
and incubated with primary antibodies overnight at 4 C, followed
by appropriate horseradish peroxidase (HRP)-conjugated second-
ary antibodies at room temperature for 2 h and later by Super
Signal Chemiluminescent Substrate (Pierce, USA). The intensity of
protein bands was analyzed using a Gel Doc XR System (Bio-Rad,
Hercules, CA, USA).
For co-IP, 200 mg proteins were incubated with 1 mg anti-STAT3
or anti-PKCz antibodies overnight (normal IgG was used as a con-
trol), followed by incubation with protein G-agarose beads (Pierce,
Rockford, IL, USA) at 4 C for 4 h. The immunoprecipitated proteins
were detected by Western blotting.
2.5. Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was extracted using Trizol reagent (Takara Biotech-
nology, Dalian, China) according to manufacturer's instruction. 1 mg
of total RNA was reverse transcribed using Thermo RevertAid First
Strand cDNA Synthesis Kit. The mRNA expression levels were
determined using SYBR-Green Quantitative PCR kit (TOYOBO,
Japan) by iCycler iQ system (iCycler, Bio-Rad, Hercules, CA, USA).
Rat-speciﬁc primers for ANF, BNP, c-fos, and aGT (listed in
Supporting Information Table S2) were synthesized by Sangon
(China). b-Actin was served as an endogenous control.
2.6. Measurement of cell surface area
Cardiomyocytes grown in 48-well plates were ﬁxed with 4%
paraformaldehyde in PBS for 15 min at room temperature, and
incubated with 0.3% Triton-X 100 for 30 min, and further incubated
with 0.1% rhodamine-phalloidin for 1 h. After washed with PBS, the
cells were incubated with DAPI (dye for the nuclei, Invitrogen) and
detected by high Content Analysis System (Thermo, ArrayScanVTI,
USA).
2.7. Immunoﬂuorescence staining
Cardiomyocytes grown on confocal dishes were treatedwith the
corresponding stimuli. After washing with PBS, the cells were ﬁxed
with 4% paraformaldehyde for 15 min at room temperature, and
permeabilized with PBS containing 0.1% Triton X-100 for another
10 min at room temperature. The cells were then blocked with 10%
goat serum for 30 min at room temperature and incubated with
mouse antibody against STAT3 (for STAT3 subcellular detection) in
10% goat serum overnight at 4 C. Then the dishes were washed and
incubated in the dark with Alexa Fluor 488-conjugated secondary
antibody at room temperature for 1 h. The nuclei were detected by
DAPI solution for 10 min in the dark at room temperature. Finally,
the dishes were washed and the images were collected using a
Zeiss LSM 510 laser confocal ﬂuorescence microscope (Carl Zeiss,
Oberkochen, Germany).
Fig. 1. Expressions of p-PKCz and p-STAT3 were increased in phenylephrine (PE)-induced cardiomyocyte hypertrophy. (A) Real-time PCR analysis showing the expressions of
fetal genes atrial natriuretic factor (ANF) and brain natriuretic polypeptide (BNP) in rat neonatal cardiomyocytes (RNCMs) treated with phenylephrine (PE) 100 mM for indicated
times. Western blotting analysis showing the expressions of (B) total PKCz and phosphorylated PKCz, and (C) total STAT3 and phosphorylated STAT3 at serine 727 (p-STAT3-Ser727)
and tyrosine 705 (p-STAT3-Tyr705) in RNCMs treated with 100 mM PE for indicated times. Data were presented as means ± SE. *p < 0.05, **p < 0.01 vs control, n ¼ 3.
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Data were presented as mean ± SE. Statistical analysis was
performed by SPSS statistic software 13.0. Statistical analysesFig. 2. PKCz overexpression enhanced hypertrophic responses in primary neonatal rat
48 h. (A) Western blotting analysis showing the protein expression of PKCz; (B) Real-time
brain natriuretic polypeptide (BNP); (C) Cell surface area measured by phalloidin staining.between two groups were performed by unpaired Student's t-test.
Differences among groups were tested by one-way analysis of
variance (ANOVA) with Tukey's post hoctest. In all cases, value of
P < 0.05 was considered statistically signiﬁcant.cardiomyocytes. Cardiomyocytes were infected with Ad-PKCz or an empty vector for
PCR analysis showing the expressions of fetal genes atrial natriuretic factor (ANF) and
Data were presented as means ± SE. *p < 0.05, **p < 0.01 vs GFP, n ¼ 3.
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3.1. Phospho-PKCz and Phospho-STAT3 levels were increased by PE
in cultured NRCMs
PE has been widely used as a stimulus of cardiac hypertrophy
in vivo and in vitro (19). In this study, primary cultured NRCMs
were incubated with 100 mM PE for indicated time points.
The mRNA expressions of the hypertrophic markers, including
ANF and BNP, were signiﬁcantly increased after PE treatment for
24 h (Fig. 1A), indicating that the model of PE-induced car-
diomyocyte hypertrophy was successfully established. In these
hypertrophic cardiomyocytes, the expression of phosphorylated
PKCz was elevated in a time-dependent manner (Fig. 1B). Since
phosphorylation of STAT3 at serine residue at amino acid posi-
tion 727 and at tyrosine 705 are responsible for its activation
(20), the effect of PE treatment on STAT3 phosphorylation was
investigated. As shown in Fig. 1C, the phosphorylation levels of
STAT3 at serine 727 and tyrosine 705 were time-dependently
augmented by PE. These observations suggest that both PKCz
and STAT3 were activated in PE-induced cardiomyocyte
hypertrophy.Fig. 3. PKCz knockdown attenuated hypertrophic responses induced by phenylephrine (
(si-PKCz) and negative control (NC) for 24 h, and were treated with or without 100 mM PE for
Real-time PCR analysis showing the expressions of fetal genes atrial natriuretic factor (ANF
staining. Data were presented as means ± SE. *p < 0.05, **p < 0.01 vs NC; #p < 0.05, ##p3.2. Effect of PKCz on cardiomyocyte hypertrophy
NRCMswere infected with Ad-PKCz or the empty vector Ad-GFP
for 48 h. The expression of PKCz was signiﬁcantly increased by Ad-
PKCz infection (Fig. 2A). The expressions of hypertrophic markers
ANF and BNP, as well as the cell surface area, were investigated. As
shown in Fig. 2B and C, the mRNA levels of ANF and BNP, as well as
the cell surface area were signiﬁcantly enhanced by Ad-PKCz
infection. These observations indicate that overexpression of PKCz
might trigger cardiomyocyte hypertrophy.
To investigate the effect of endogenous PKCz on PE-induced
cardiomyocyte hypertrophy, PKCz was knocked down by RNA
interference in NRCMs. After comparing the silencing efﬁcacy of
three different siRNA for PKCz (S1, S2, and S3), S3 was chosen for
the following experiments since it showed the best silencing efﬁ-
cacy (Supplementary Fig. S1). The result in Fig. 3A conﬁrmed that
PKCz silencing using S3 inhibited the expression of PKCz in the
presence or absence of PE. Knockdown of PKCz prevented car-
diomyocyte from PE-stimulated hypertrophy, as revealed by the
decrease of mRNA levels of ANF and BNP (Fig. 3B), as well as the cell
surface area (Fig. 3C). These results suggest that endogenous PKCz is
involved in PE-induced cardiomyocyte hypertrophy.PE) treatment. Primary neonatal rat cardiomyocytes were transfected with PKCz siRNA
another 24 h. (A) Western blotting analysis showing the protein expression of PKCz; (B)
) and brain natriuretic polypeptide (BNP); (C) Cell surface area measured by phalloidin
< 0.01 vs NC þ PE. n ¼ 3.
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NRCMs were transfected with pEGFP-STAT3 plasmid or an
empty vector N3 for 48 h. Fig. 4A showed that STAT3 was overex-
pressed by transfection of STAT3 plasmid. As shown in Fig. 4B and C,
themRNA expressions of the hypertrophic markers ANF and BNP, as
well as the cell surface area were signiﬁcantly increased by STAT3
overexpression, suggesting that STAT3 deteriorates cardiomyocyte
hypertrophy.3.4. PKCz interacted with STAT3 in NRCMs
To explore whether PKCz interacts with STAT3 in NRCMs, co-IP
experiments were conducted in NRCMs treated with or without
PE, or in cells overexpressed PKCz or STAT3. As shown in Fig. 5A and
B, there are interactions between PKCz and STAT3, no matter in
control cells, PE-treated cells, or cells with PKCz or STAT3
overexpression.Fig. 4. STAT3 overexpression enhanced hypertrophic responses in primary neonatal rat
with pEGFP-STAT3 plasmid for 48 h. (A) Western blotting analysis showing the protein expre
natriuretic factor (ANF) and brain natriuretic polypeptide (BNP); (C) Cell surface area measur
Fig. 5. PKCz interacted with STAT3 in cardiomyocytes. Co-IP assay was performed to invest
were treated with 100 mM PE for 24 h (PE group) or were transfected STAT3 plasmid (STAT3 g
anti-PKCz antibody (CON, PE, and STAT3 groups) or anti-IgG antibody (IgG group). Express
cardiomyocytes were treated with 100 mM PE for 24 h (PE group) or were infected with PK
immunoprecipitated with anti-STAT3 antibody (CON, PE, and Ad-PKCz groups) or anti-IgG an
Expressions of STAT3 and PKCz in protein extracts without immunoprecipitation were detect
3 independent experiments were shown.3.5. PKCz enhanced activation and nuclear translocation of STAT3
Since PKCz regulates a series of transcription factors and protein
kinases by phosphorylating their serine or threonine residues (21),
it is hypothesized that PKCz phosphorylates STAT3 to evoke STAT3
activation. To investigate the exact role of PKCz in STAT3 activation,
NRCMs were infected with Ad-PKCz, or transfected with PKCz
siRNA. As shown in Fig. 6A, Ad-PKCz signiﬁcantly augmented the
phosphorylated level of STAT3 both at Ser727 and Tyr705 without
affecting its total protein level. The effect of PKCz overexpression on
STAT3 activationwas resembled as that of PE treatment. In contrary,
PKCz knockdown reversed PE-induced upregulation of phosphor-
ylated STAT3 (Fig. 6B).
After activation, STAT3 is transported from the cytoplasm to the
nucleus to regulate the transcription of its target genes (22). Thus,
the nuclear translocation of STAT3was investigated by determining
the expression of STAT3 in the nuclear fractions of NRCMs and by
detecting the subcellular distribution of STAT3 under confocal mi-
croscope. A marked increase of phosphorylated STAT3 (at bothcardiomyocytes. STAT3 was transiently overexpression in neonatal rat cardiomyocytes
ssion of STAT3; (B) Real-time PCR analysis showing the expressions of fetal genes atrial
ed by phalloidin staining. Data were presented as means ± SE. **p < 0.01 vs GFP, n ¼ 3.
igate the interaction between PKCz and STAT3. (A) Primary neonatal rat cardiomyocytes
roup). Total protein extracted from the cardiomyocytes were immunoprecipitated with
ions of STAT3 and PKCz were detected by Western blotting. (B) Primary neonatal rat
Cz adenovirus (Ad-PKCz group). Total protein extracted from the cardiomyocytes were
tibody (IgG group). Expressions of PKCz and STAT3 were detected by Western blotting.
ed by Western blotting and were served as input controls. Representative images out of
Fig. 6. Effect of PKCz on the activation and nuclear translocation of STAT3 in primary neonatal rat cardiomyocytes. (A) and (C) Cardiomyocytes were infected with adenovirus
overexpressing PKCz or GFP control for 48 h. Western blotting analysis showing the phosphorylated levels of STAT3 at Ser727 and Tyr705, as well as the total STAT3 expression in (A)
total protein extracts and (C) nuclear protein extracts. *p < 0.05, **p < 0.01 vs GFP, n ¼ 3. (B) and (D) Cardiomyocytes were transfected with PKCz siRNA (si-PKCz) or negative control
(NC) for 24 h, and were treated with or without 100 mM phenylephrine (PE) for another 24 h. Western blotting analysis showing the phosphorylated levels of STAT3 at Ser727 and
Tyr705, as well as total STAT3 expression in (B) total protein extracts and (D) nuclear protein extracts. Data were presented as means ± SE. *p < 0.05, **p < 0.01 vs NC, n ¼ 3.
#p < 0.05, ##p < 0.01 vs NC þ PE, n ¼ 3. (E) Immunoﬂuorescence of STAT3 by confocal microscopy showing the subcellular location of STAT3 in neonatal rat cardiomyocytes infected
with Ad-PKCz or transfected with si-PKCz or in the presence of PE. Bar ¼ 10 mm.
J. Li et al. / Journal of Pharmacological Sciences 132 (2016) 15e23 21Ser727 and Tyr705) and total STAT3 in the nuclear fractions was
shown in cardiomyocytes treated with PE or infected with Ad-PKCz
(Fig. 6C). By contrast, PE-induced upregulation of nuclear expres-
sions of STAT3, phosphorylated STAT3 at Ser727 and Tyr705, were
signiﬁcantly reversed by si-PKCz (Fig. 6D). In addition, the ﬂuo-
rescence of STAT3 was assembled in the nucleus of NRCMs with PE
treatment or PKCz overexpression, but remained in the cytoplasm
in the control cells or cells silencing PKCz (Fig. 6E).
Taken together, these results indicate that PKCz promotes the
activation and nuclear shuttling of STAT3 in NRCMs, probably
leading to cardiomyocyte hypertrophy.
3.6. Effect of PKCz on the expressions of STAT3 target genes
To conﬁrm the role of PKCz in the regulation of the transcrip-
tional activity of STAT3, the expressions of STAT3 target genes c-fos
and aGT were investigated. Exposure to PE increased the mRNA
levels of these target genes (Fig. 7A and B). Similarly, over-
expression of PKCz augmented the mRNA expressions of these
genes (Fig. 7A). However, knockdown of PKCz suppressed the ex-
pressions of c-fos and aGT induced by PE (Fig. 7A). These obser-
vations indicate that PKCz enhances the transcriptional activity of
STAT3 in cardiomyocyte hypertrophy.
4. Discussion
The present study demonstrates an interaction between PKCz
and STAT3 in cardiomyocytes. PKCz favors the phosphorylation and
activation of STAT3, triggers its nuclear transport, and subsequently
elevates the expressions of its downstream target genes. The
regulation of STAT3 by PKCz contributes to the development of
cardiomyocyte hypertrophy.
PKC is a family of serine/threonine kinases consisting of 11
different isoenzymes that are divided into three subgroups depen-
dent on the activation mode. The activation of conventional PKC
isoforms (a, b1, b2, and g) relies on Ca2þ, phospholipids such as
dioleoylglycerol (DAG) and phosphatidylserine (PS). The novel PKC
isoforms (d, ε, h, and q) are Ca2þ-independent, but require DAG and
PS for theiractivation. Bothgroups canbeactivatedbyphorbol esters
like phorbol-12,13-myristate-acetate (PMA). However, the atypical
subfamily of PKC lacks the sensitivity to Ca2þ and DAG/PMA (23).
In cardiac hypertrophy, the conventional PKC isoforms a and b
(24e27), and novel PKC isoforms d and ε (25, 28e30), are generallyFig. 7. Effect of PKCz on the transcriptional activity of STAT3. Real-time PCR analysis show
cultured neonatal rat cardiomyocytes. (A) infected with PKCz adenovirus or GFP control for
and were treated with or without 100 mM phenylephrine (PE) for another 24 h. Data were pr
NC; #p < 0.05, ##p < 0.01 vs NC þ PE, n ¼ 3.upregulated and activated. Their increased expression and activa-
tion signiﬁcantly promote the development of cardiac hypertrophy
(24e30). PKC isoforms g and t is unaltered or decreased in cardiac
hypertrophymodels, and is not involved in the regulation of cardiac
contractility and heart failure (31e33). Since mechanisms under-
lying the regulation of conventional and novel PKC isoforms in
cardiac hypertrophy have been extensively reported, the present
study focus on the effect of atypical PKC (PKCz) on cardiac
hypertrophy.
PKCz, a member of the atypical PKC subfamily, has been re-
ported to present in cardiomyocyte (34) and participate in the
regulation of cardiomyocyte myoﬁlament protein phosphorylation
(21). In this study, the expression of phosphorylated PKCz was
signiﬁcantly increased in a model of cardiomyocyte hypertrophy
induced by PE (Fig. 1), suggesting that PKCz was activated in car-
diomyocyte hypertrophy. Additionally, PKCz overexpression
enhanced the hypertrophic responses in cultured NRCMs (Fig. 2),
while genetic silencing of PKCz protected NRCMs from PE-induced
hypertrophy (Fig. 3). Thus, these observations provide solid evi-
dence for the role of PKCz in cardiomyocyte hypertrophy. Consis-
tent with our observations, it is reported that PKCz is upregulated in
the left ventricle of hypertrophic hearts induced by volume over-
load and pressure overload (1e3), and that the phosphorylation
level of PKCz at Thr410 is elevated in aortic clamping hearts (2).
STAT3 has been implicated to be involved cardiac hypertrophy.
STAT3 plays an essential role in mediating survival of cardiac
myocytes (7e9). Cardiac-speciﬁc overexpression of STAT3 in
transgenic mice leads to the development of myocardial hyper-
trophy (7). In line with these studies, this study showed a signiﬁ-
cant increase of phosphorylated STAT3 in PE-induced
cardiomyocyte hypertrophy (Fig. 1). Overexpression of STAT3
mimicked the hypertrophic responses, as viewed by the increase of
ANF, BNP and cell surface area (Fig. 4).
Given that PKCz and STAT3 are closely associated with car-
diomyocyte hypertrophy, it is hypothesized that the crosstalk be-
tween these two deleterious factors maybe play an important role
in pathological myocardial hypertrophy. The co-IP results clearly
demonstrated an interaction between PKCz and STAT3 in car-
diomyocytes with or without PE treatment (Fig. 5). Although it is
reported that PKCz can regulate the phosphorylation of STAT3 at
tyrosine and serine residues (15), currently there is no information
concerning the effects of PKCz on STAT3 in cardiac cells. The present
study demonstrated that overexpression of PKCz with adenovirusing the mRNA levels of STAT3 target genes c-fos and angiotensinogen (aGT) in primary
48 h and (B) transfected with PKCz siRNA (si-PKCz) and negative control (NC) for 24 h,
esented as means ± SE. (A) *p < 0.05, **p < 0.01 vs GFP, n ¼ 3. (B) *p < 0.05, **p < 0.01 vs
J. Li et al. / Journal of Pharmacological Sciences 132 (2016) 15e2322infection enhanced the phosphorylated levels of STAT3 at both
Ser727 and Tyr705 without altering the expression of total STAT3
(Fig. 6A). Moreover, silencing of PKCz attenuated PE-induced in-
crease of the phosphorylated levels of STAT3 (Fig. 6B). Thus, these
results conﬁrm the regulatory role of PKCz in the activation of
STAT3 in cardiomyocyte hypertrophy.
STAT3, as a latent cytoplasmic transcription factor, is activated
when its Tyr705 site is phosphorylated. The activated STAT3 forms
a dimer and shuttles to the nucleus, where it binds to promoter
elements and regulates the expressions of numerous genes (22).
Interestingly, the phosphorylation of C-terminal Ser727 residue of
STAT3 is also important, since it is essential for maximizing the
transcriptional activity of STAT3 (20). Indeed, STAT3 was trans-
ported to the nucleus after phosphorylated by PKCz at both Tyr705
and Ser727, as implied by the Western blotting data detecting the
nuclear expressions of STAT3 and phosphorylated STAT3, as well as
the immunoﬂuorescent results directly showing the translocation
of STAT3 (Fig. 6C, D & E). Moreover, PKCz enhanced the mRNA ex-
pressions of c-fos and aGT (Fig. 7), which are target genes of STAT3
and are associated with cardiac hypertrophy (8, 14, 35). This result
further conﬁrms the role of PKCz in the transcriptional activation of
STAT3, which promotes the pathogenesis of cardiac hypertrophy.
The exact mechanism by which PKCz mediates STAT3 phos-
phorylation is still not clear. As a serine/threonine kinase, it is not
surprising that PKCz phosphorylates the Ser727 site of STAT3, since
the amino acid sequence of STAT3 Ser727 coincides with the
consensus phosphorylation site motifs for PKCz (36) and Ser727
directly serves as a substrate for PKCz. However, the phosphoryla-
tion of STAT3 Tyr705 by PKCz seems puzzled. One possible expla-
nation is that the phosphorylation of Tyr705 might be a
downstream cascade following Ser727 phosphorylation, which it is
proved to maximize the transcriptional activity of STAT3 (37).
Another explanation is that PKCz may phosphorylate Tyr705 indi-
rectly, possibly via intermediate factors like Jak activation (38). The
exact mechanisms underlying the regulation of PKCz on STAT3
need to be further elucidated.
As a limitation, the present study only investigated the inter-
action between PKCz and STAT3 in PE-induced cardiomyocyte hy-
pertrophic model. Further studies using in vivo cardiac
hypertrophic animal models, such as abdominal aortic constriction
and angiotensin II perfusion, should be elucidated to unmask the
exact role of PKCz and STAT3 in the development of cardiac
hypertrophy.
In conclusion, the present study demonstrates that PKCz in-
teracts with STAT3 in cardiomyocytes. PKCz might promote the
development of cardiomyocyte hypertrophy via activation of STAT3
signaling. Strategies targeting inhibition of PKCz-STAT3 signaling
pathway suggest a therapeutic potential for cardiac hypertrophy.
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